Brazil's health regulatory agency, Anvisa, authorized the national production of the chikungunya vaccine on Monday [5].
This move allows the country to manufacture the vaccine domestically, reducing reliance on imports and facilitating the integration of the shot into the Sistema Único de Saúde (SUS), the nation's public health system.
The vaccine, known as XCHIQ, was developed by the Instituto Butantan in partnership with Valneva [1]. Production will take place at the Instituto Butantan facilities in São Paulo [3]. While Anvisa first approved the vaccine in April 2025 [4], this latest authorization specifically permits the domestic manufacturing process.
The decision comes as Brazil faces a significant public health challenge from the virus. Reports indicate more than 127,000 cases of chikungunya [1] and 125 deaths [1] within the country.
The XCHIQ vaccine is currently indicated for adults between 18 and 59 years of age [3]. By producing the vaccine locally, the government aims to increase national vaccine capacity and ensure a more stable supply for the population.
Officials said the authorization is a critical step in addressing the impact of the disease. The partnership between the public institute and the private firm Valneva allows Brazil to leverage international research while maintaining national sovereignty over the production of essential medicines.
“Anvisa authorized the national production of the chikungunya vaccine on Monday.”
The transition from importing a vaccine to domestic production marks a strategic shift in Brazil's health security. By utilizing the Instituto Butantan, the government can lower the per-dose cost and accelerate the rollout of the vaccine through the SUS, potentially reducing the long-term economic and healthcare burden caused by the high volume of chikungunya cases.
